Outcomes in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Receiving Inotuzumab Ozogamicin Stratified by Cumulative Dose


Por: Jabbour, E, Advani, A, Gokbuget, N, Ribera, J, Stock, W, Cassaday, R, DeAngelo, DJ, Dorman, S, Williams, S, Zhang, F, Vandendries, E and Kantarjian, H

Publicada: 1 sep 2025
Resumen:


Filiaciones:
Jabbour, E:
 Univ Texas MD Anderson Canc Ctr, Houston, TX USA

Advani, A:
 Cleveland Clin, Cleveland, OH USA

Gokbuget, N:
 Goethe Univ Hosp, Frankfurt, Germany

:
 Inst Catala Oncol, Barcelona, Spain

 Josep Carreras Res Inst, Barcelona, Spain

Stock, W:
 Univ Chicago, Chicago, IL USA

Cassaday, R:
 Univ Washington, Sch Med, Seattle, WA USA

 Fred Hutchinson Canc Ctr, Seattle, WA USA

DeAngelo, DJ:
 Dana Farber Canc Inst, Boston, MA USA

Dorman, S:
 Pfizer Inc, St Catharines, ON, Canada

Williams, S:
 Pfizer Inc, Columbus, OH USA

Zhang, F:
 Pfizer Inc, San Diego, CA USA

Vandendries, E:
 Pfizer Inc, Cambridge, MA USA

Kantarjian, H:
 Univ Texas MD Anderson Canc Ctr, Houston, TX USA
ISSN: 21522650





Clinical Lymphoma Myeloma & Leukemia
Editorial
Cancer Media Group, 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA, Estados Unidos America
Tipo de documento: Meeting Abstract
Volumen: 25 Número:
Páginas:
WOS Id: 001606305100047

MÉTRICAS